Obesity

PHILADELPHIA — In the SELECT trial, treatment with weekly injectable semaglutide 2.4 mg was superior to placebo for reducing cardiovascular risk in adults with preexisting heart disease and overweight or obesity but without diabetes.

Weight loss presented as a positive opportunity by physicians was associated with greater uptake of treatment and weight loss, a study published in Annals of Internal Medicine found.

WASHINGTON —Pediatric obesity and guidelines on how to manage it were the focus of several symposiums at the AAP National Conference & Exhibition.

DENVER — A primary care-based lifestyle course improved several health behaviors in Appalachia, according to the results of research presented at the American College of Lifestyle Medicine’s annual meeting.

The FDA approved the injectable GIP/GLP-1 dual incretin-based agonist tirzepatide for chronic weight management among adults with obesity, according to a press release.

The recommendation that people living with diabetes should avoid carbohydrates is misguided, according to a speaker at the Lifestyle Medicine Conference.

Researchers observed a dose-dependent relationship between increasing maternal BMI and higher postpartum infection risk after different delivery modes, according to findings published in The Journal of Maternal-Fetal & Neonatal Medicine.

According to published results, patients with osteoporosis had a two-fold increased risk for revision for periprosthetic fracture at 5 years after total knee arthroplasty compared with patients without osteoporosis.

Adults with type 2 diabetes and obesity achieved greater weight loss with time-restricted eating at 6 months than with calorie restriction or continuing usual eating habits, according to study data.

GLP-1 receptor agonists appear to be an effective way of cutting down on obesity. But there are important adverse events — and ways to avoid them — that patients should be made aware of, according to experts.